IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–R

Single-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to data from a phase 1 trial.

Related Keywords

China , Tianjin , Jingwei Yu , Tianjin Medical University Cancer Institute Hospital , , Tianjin Medical University Cancer Institute , Ann Arbor , Ibi322 , Classical Hodgkin Lymphoma , Lymphoma , Eha Congress , Hematologic ,